This study will explore the contribution of CBD oral drops in persons experiencing symptoms of Post Acute COVID Syndrome or "PACS".

At present, conventional medical and rehabilitation therapies have not consistently been effective for people with PACS, and in fact some symptoms have been observed to worsen over time. This inconsistency in clinical response has created a need for alternative treatment options to be explored. CBD presents a novel approach that warrants further investigation.

After review and approval by an Institutional Review Board (IRB), potential study participants will be recruited from on-line support groups who have identified themselves as persons experiencing post-acute COVID-19 syndrome also known as (long-haulers syndrome).

The study will be registered on the www.clincaltrials.gov website and will accept referrals from targeted clinics who refer their patients to the investigational site listed and individuals can also self-refer to the study center team.

Subjects will be evaluated weekly using telemedicine procedures. At completion of study, there will be a 7-day and 14-day follow up telemedicine visit to assess for continued benefit and/or re-emergence of symptoms/relapse.

Inclusion Criteria:

1. Age 18 years of age or older who can provide informed consent.
2. Persons who have been diagnosed with COVID-19 and now in post-acute recovery phase.
3. Persons who are in care with access to primary care for post COVID infection or PACS.
4. Ability to read and write in the English language and follow study-related procedures.
5. Ability to have mail/ study drug delivered to an address and/or P.O. Box in the recipient's name.
6. Ability to participate in telemedicine visits/communication.
7. If a woman of childbearing age, willing to use a dual method of contraception (barrier and/or hormonal).

Exclusion Criteria:

1. Active illicit or non-prescribed drug use.
2. Concomitant use of benzodiazepines.
3. Concomitant use of an immune suppressant agent, e.g., prednisone.
4. Documented history and active treatment for seizure disorder.
5. Transaminase elevation.
6. Active autoimmune disorder.
7. Hepatitis C infection (currently on therapy and/or any transaminitis elevation).
8. Hepatitis B infection (currently on therapy and/or any transaminitis elevation).
9. Human Immune Deficiency Virus (HIV-1 or HIV-2) infection that is newly diagnosed or untreated.
10. Any form of mental impairment that will/could hinder safe participation in the study.
11. Pregnancy or breast-feeding.
12. Any condition that in the opinion of the investigator would be harmful or detrimental to the participant.

Treatment period 1 will utilize masked study product labels with subject ID. Treatment period 1 will utilized unmasked / open-label study product with subject ID.